Sébastien Thureau1, Lucie Lebret2, Justine Lequesne3, Marine Cabourg4, Simon Dandoy2, Céline Gouley5, Laureline Lefebvre2, Romain Mallet2, Sorina-Dana Mihailescu3, Cristian Moldovan4, Olivier Rigal4,5, Ovidiu Veresezan2, Romain Modzewelski6, Florian Clatot4. 1. Department of Radiation Oncology, Henri Becquerel Cancer Center & QuantIF-LITIS [EA (Equipe d'Accueil) 4108], 76038 Rouen, France. 2. Department of Radiation Oncology, Henri Becquerel Cancer Center, 76038 Rouen, France. 3. Department of Statistics and Clinical Research Unit, Henri Becquerel Cancer Center, 76038 Rouen, France. 4. Department of Medical Oncology, Henri Becquerel Cancer Center, 76038 Rouen, France. 5. Department of Supportive Cancer, Henri Becquerel Cancer Center, 76038 Rouen, France. 6. Department of Nuclear Medicine, Henri Becquerel Cancer Center & QuantIF-LITIS [EA (Equipe d'Accueil) 4108-FR CNRS 3638], Faculty of Medicine, University of Rouen, 76130 Rouen, France.
Abstract
Highlights: Sarcopenia is frequent in patients treated with radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinomas. Sarcopenia is associated with poor disease-free survival and overall survival outcomes. Sarcopenia is not associated with a higher rate of treatment-related toxicity. Background: Sarcopenia occurs frequently with the diagnosis of head and neck squamous cell carcinoma (HNSCC). We aimed to assess the impact of sarcopenia on survival among HNSCC patients treated with radiotherapy (RT) or radiochemotherapy (RTCT). Methods: Patients treated between 2014 and 2018 by RT or RTCT with curative intent were prospectively included (NCT02900963). Optimal nutritional support follow-up, including weekly consultation with a dietician and an oncologist and daily weight monitoring, was performed. Sarcopenia was determined by measuring the skeletal muscles at the L3 vertebra on the planning CT scan for radiotherapy. For each treatment group (RT or RTCT), we assessed the prognostic value of sarcopenia for disease-free survival (DFS) and overall survival (OS) and its impact on treatment-related toxicity. Results: Two hundred forty-three HNSCC patients were included: 116 were treated by RT and 127 were treated by RTCT. Before radiotherapy, eight (3.3%) patients were considered malnourished according to albumin, whereas 88 (36.7%) patients were sarcopenic. Overall, sarcopenia was associated with OS and DFS in a multivariate analysis (HR 1.9 [1.1-3.25] and 1.7 [1.06-2.71], respectively). It was similar for patients treated with RT (HR 2.49 [1.26-4.9] for DFS and 2.24 [1.03-4.86] for OS), whereas for patients treated with RTCT sarcopenia was significantly associated with OS and DFS in univariate analysis only. Sarcopenia was not related to higher treatment-related toxicity. Conclusions: Pretherapeutic sarcopenia remains frequent and predicts OS and DFS for non-frail patients treated with curative intent and adequate nutritional support.
Highlights: Sarcopenia is frequent in patients treated with radiation therapy (RT) or radiochemotherapy (RTCT) for head and neck squamous cell carcinomas. Sarcopenia is associated with poor disease-free survival and overall survival outcomes. Sarcopenia is not associated with a higher rate of treatment-related toxicity. Background: Sarcopenia occurs frequently with the diagnosis of head and neck squamous cell carcinoma (HNSCC). We aimed to assess the impact of sarcopenia on survival among HNSCCpatients treated with radiotherapy (RT) or radiochemotherapy (RTCT). Methods:Patients treated between 2014 and 2018 by RT or RTCT with curative intent were prospectively included (NCT02900963). Optimal nutritional support follow-up, including weekly consultation with a dietician and an oncologist and daily weight monitoring, was performed. Sarcopenia was determined by measuring the skeletal muscles at the L3 vertebra on the planning CT scan for radiotherapy. For each treatment group (RT or RTCT), we assessed the prognostic value of sarcopenia for disease-free survival (DFS) and overall survival (OS) and its impact on treatment-related toxicity. Results: Two hundred forty-three HNSCCpatients were included: 116 were treated by RT and 127 were treated by RTCT. Before radiotherapy, eight (3.3%) patients were considered malnourished according to albumin, whereas 88 (36.7%) patients were sarcopenic. Overall, sarcopenia was associated with OS and DFS in a multivariate analysis (HR 1.9 [1.1-3.25] and 1.7 [1.06-2.71], respectively). It was similar for patients treated with RT (HR 2.49 [1.26-4.9] for DFS and 2.24 [1.03-4.86] for OS), whereas for patients treated with RTCTsarcopenia was significantly associated with OS and DFS in univariate analysis only. Sarcopenia was not related to higher treatment-related toxicity. Conclusions: Pretherapeutic sarcopenia remains frequent and predicts OS and DFS for non-frail patients treated with curative intent and adequate nutritional support.
Entities:
Keywords:
head and neck squamous cell carcinomas; radiochemotherapy; radiotherapy; sarcopenia
Authors: Amy L Shaver; Mary E Platek; Anurag K Singh; Sung Jun Ma; Mark Farrugia; Gregory Wilding; Andrew D Ray; Heather M Ochs-Balcom; Katia Noyes Journal: BMC Cancer Date: 2022-06-22 Impact factor: 4.638
Authors: Aniek T Zwart; Wolf Pörtzgen; Irene van Rijn-Dekker; Grigory A Sidorenkov; Rudi A J O Dierckx; Roel J H M Steenbakkers; Inge Wegner; Anouk van der Hoorn; Geertruida H de Bock; Gyorgy B Halmos Journal: J Clin Med Date: 2022-08-09 Impact factor: 4.964